Press release
From Detection to Action: Enloq Unveils Applied AI Breakthrough in Security Operations
Researchers at Enloq have developed an AI agent that unifies video detection, contextual reasoning, and automated actions. Tailored for high-stakes environments such as logistics hubs, critical infrastructure, and private security, the platform integrates seamlessly with current security technology to cut response times, reduce costs, and strengthen proactive defense.Enloq, a new entrant in the video-security technology space, today announced the launch of its AI vision agent, designed to transform how Global Security Operations Centers (GSOCs), logistics firms, and critical infrastructure sites respond to incidents.
Unlike traditional video analytics that only classify objects or basic events, Enloq's system integrates real-time detection with LLM reasoning and direct actuation of security infrastructure-cutting mean time to resolution dramatically.
"In our trials, we've seen that it's not enough just to know there's a breach," said Nikolaos, CEO & Co-founder of Enloq. "Operators need tools that do more than flag-they need partners that act. Our system bridges that gap by turning detection into decisions and action, all within existing infrastructure and under 45 seconds."
Key Features
*
Compatibility with standard ONVIF/RTSP cameras and major VMS systems
*
Agent-led actions such as door locking/unlocking, voice notifications via IP speakers, and automatic incident report & ticket generation
*
Edge-efficient operation to minimize latency and cost
*
Prompt-driven deployment and customizable rule-setting
Building on early deployments of its archived investigation tool, Enloq is now opening access to pilots for live agent functionality across the USA and MENA regions.
"Security operations are under pressure everywhere-from rising costs and high employee turnover to alert fatigue," said Pranu, CTO at Enloq. "We believe that letting AI act when it senses a genuine threat, rather than waiting for manual intervention, is the next frontier in operational excellence."
Media Contact
Company Name: Enloq
Contact Person: Nikolaos Komianos
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=from-detection-to-action-enloq-unveils-applied-ai-breakthrough-in-security-operations]
Country: United States
Website: https://www.enloq.co/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release From Detection to Action: Enloq Unveils Applied AI Breakthrough in Security Operations here
News-ID: 4186933 • Views: …
More Releases from ABNewswire

Primary Biliary Cholangitis Market Expected to Gain Momentum Through 2034, Accor …
The Key Primary Biliary Cholangitis Companies in the market include - CymaBay Therapeutics, Inc., Zydus Therapeutics Inc., Gannex Pharma Co., Ltd., Nanjing Chia-tai Tianqing Pharma, Novartis, Merck Sharp & Dohme LLC, Mirum Pharmaceuticals, Inc., Genfit, CymaBay Therapeutics, Inc., Calliditas Therapeutics, HighTide Biopharma Pty Ltd, Albireo, Curome Biosciences, Tobira Therapeutics, Inc., Pliant Therapeutics, Inc., Biotie Therapies Corp., and others.
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an…

Birch Allergy Market Trends Point to Steady Growth Ahead by 2034, DelveInsight A …
The Key Birch Allergy Companies in the market include - ALK-Abello A/S, Allergy Therapeutics Plc., Regeneron Pharmaceuticals Inc., Desentum., HAL Allergy Group., Roxall Medizin GmbH., Worg Pharmaceuticals AG., S-TARget therapeutics GmbH., Adamis Pharmaceuticals Crp., and others .
DelveInsight's "Birch Allergy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Birch Allergy, historical and forecasted epidemiology as well as the Birch Allergy market trends in the United States,…

Pegasus Angel Accelerator Portfolio Company MedSetGo Closes $2.4M Oversubscribed …
MedSetGo, a Pegasus Angel Accelerator portfolio company, closed an oversubscribed $2.4M seed round led by TurboStart with support from Gold House Ventures. The AI-driven healthcare startup is modernizing patient care transitions and will use the funding to accelerate product development and hiring.
SANTA MONICA, September 17, 2025 - Pegasus Angel Accelerator [https://www.pegasusangelaccelerator.com/?utm_source=pr&utm_medium=google&utm_campaign=ABNews] is proud to announce that MedSetGo [https://medsetgo.ai/], one of its portfolio companies, has successfully closed a $2.4 million seed…

Melanoma Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Melanoma pipeline constitutes 150+ key companies continuously working towards developing 170+ Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Melanoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/melanoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Melanoma Market.
The Melanoma Pipeline report embraces in-depth commercial and clinical…